Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Lung Cancer

• Publication date

  2015-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2015.10.005PMID 26505137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer.

  2015cited by this paper
• Targeting cancer-derived adenosine: new therapeutic approaches.

  2014cited by this paper
• Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells

  2014cited by this paper
• Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors

  2014cited by this paper
• Therapeutic Potentials of Ecto‐Nucleoside Triphosphate Diphosphohydrolase, Ecto‐Nucleotide Pyrophosphatase/Phosphodiesterase, Ecto‐5′‐Nucleotidase, and Alkaline Phosphatase Inhibitors

  2014cited by this paper
• Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.

  2014cited by this paper
• Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.

  2014cited by this paper
• 2-Hexylthio-β,γ-CH2-ATP is an effective and selective NTPDase2 inhibitor.

  2014cited by this paper
• Purinergic signalling and cancer

  2013cited by this paper
• Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors.

  2013cited by this paper
• ENTPD1/CD39 is a promising therapeutic target in oncology

  2013cited by this paper
• Purinergic P2Y₂ receptors promote neutrophil infiltration and hepatocyte death in mice with acute liver injury.

  2012cited by this paper
• Purinergic Signaling in the Airways

  2012cited by this paper
• Enzyme-coupled assays for simultaneous detection of nanomolar ATP, ADP, AMP, adenosine, inosine and pyrophosphate concentrations in extracellular fluids.

  2012cited by this paper
• Autocrine regulation of TGF-&bgr;1-induced cell migration by exocytosis of ATP and activation of P2 receptors in human lung cancer cells

  2012cited by this paper
• Purinergic signaling during inflammation.

  2012cited by this paper
• Lung cancer alters the hydrolysis of nucleotides and nucleosides in platelets.

  2012cited by this paper
• P2X7 receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness

  2011cited by this paper
• Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.

  2011cited by this paper
• Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor

  2010cited by this paper
• Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and Emphysema

  2010cited by this paper
• Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.

  2010cited by this paper
• Extracellular adenosine triphosphate and chronic obstructive pulmonary disease.

  2010cited by this paper
• CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.

  2010cited by this paper
• Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

  2010cited by this paper
• Effect of adenosine 5′-triphosphate infusions on the nutritional status and survival of preterminal cancer patients

  2009cited by this paper
• Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

  2009cited by this paper
• Chemotherapy induces ATP release from tumor cells

  2009cited by this paper
• Activation of Human Alveolar Macrophages via P2 Receptors: Coupling to Intracellular Ca2+ Increases and Cytokine Secretion1

  2008cited by this paper
• Effect of extracellular ATP on the growth of hormone‐refractory prostate cancer in vivo

  2008cited by this paper
• Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease?

  2008cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice.

  2007cited by this paper
• The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism.

  2006cited by this paper
• Cryopyrin activates the inflammasome in response to toxins and ATP

  2006cited by this paper
• Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

  2006cited by this paper
• Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

  2006cited by this paper
• Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth.

  2005cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Early prostate cancer detected using expression of non‐functional cytolytic P2X7 receptors

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells.

  2004cited by this paper
• ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells.

  2003cited by this paper
• Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells.

  2003cited by this paper
• Promising effects of adenosine triphosphate infusion on nutritional status and quality of life in advanced non‐small‐cell lung cancer: a randomized clinical trial

  2003cited by this paper
• Growth inhibition of lung cancer cells by adenosine 5′‐triphosphate

  2003cited by this paper
• Adenosine acts through an A3 receptor to prevent the induction of murine anti‐CD3‐activated killer T cells

  2002cited by this paper
• Processing of gene expression data generated by quantitative real-time RT-PCR.

  2002cited by this paper
• Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial.

  2002cited by this paper
• Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer.

  2000cited by this paper
• Primer3 on the WWW for general users and for biologist programmers.

  2000cited by this paper
• Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer.

  2000cited by this paper
• Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer

  2000cited by this paper
• Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells.

  2000cited by this paper
• Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer

  1998cited by this paper
• The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.

  1997cited by this paper
• Adenosine inhibits the adhesion of anti-CD3-activated killer lymphocytes to adenocarcinoma cells through an A3 receptor.

  1994cited by this paper

• P2X7 receptor: a potential therapeutic target for chronic respiratory diseases

  2025cites this paper
• The Ectonucleotidases CD39 and CD73 and the Purinergic Receptor P2X4 Serve as Prognostic Markers in Non-Small Cell Lung Cancer

  2025influential citation
• Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy

  2024cites this paper
• Role and Therapeutic Potential of P2X7 Receptor in Lung Cancer Progression.

  2024cites this paper
• P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K/Akt pathways

  2023cites this paper
• Purinergic signaling: Diverse effects and therapeutic potential in cancer

  2023cites this paper
• A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer

  2023cites this paper
• [Interference of P2X4 receptor expression in tumor-associated macrophages suppresses migration and invasion of glioma cells].

  2022cites this paper
• The Purinergic Landscape of Non-Small Cell Lung Cancer

  2022cites this paper
• Relevance of lysosomal Ca2+ signalling machinery in cancer.

  2022cites this paper
• Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer

  2022cites this paper
• Research Progress in the Relationship Between P2X7R and Cervical Cancer

  2022cites this paper
• Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy

  2021cites this paper
• AMP hydrolysis reduction in blood plasma of breast cancer elderly patients after different treatments

  2021cites this paper
• P2X Receptors: Potential Therapeutic Targets for Symptoms Associated With Lung Cancer — A Mini Review

  2021cites this paper
• The role of genetic polymorphisms in endolysosomal ion channels TPC2 and P2RX4 in cancer pathogenesis, prognosis, and diagnosis: a genetic association in the UK Biobank

  2021cites this paper
• To inhibit or to boost the ATP/P2RX7 pathway to fight cancer—that is the question

  2021cites this paper
• Is the regulation by miRNAs of NTPDase1 and ecto-5’-nucleotidase genes involved with the different profiles of breast cancer subtypes?

  2021cites this paper
• The role of genetic polymorphisms in endolysosomal ion channels TPC2 and P2RX4 in cancer pathogenesis, prognosis, and diagnosis: a genetic association in the UK Biobank

  2021cites this paper
• P2Y Receptors for Extracellular Nucleotides: Contributions to Cancer Progression and Therapeutic Implications.

  2021cites this paper
• Autocrine and paracrine purinergic signaling in the most lethal types of cancer

  2021cites this paper
• The Dual Effect of CD28 on The Prognosis of Lung Cancer Based On Nomograms: A Comprehensive Analysis of The Tumor Immune Microenvironment

  2020cites this paper
• Characteristics and the role of purinergic receptors in pathophysiology with focus on immune response

  2020cites this paper
• P2X7 in Cancer: From Molecular Mechanisms to Therapeutics

  2020cites this paper
• The role and pharmacological characteristics of ATP-gated ionotropic receptor P2X in cancer pain.

  2020cites this paper
• The P2X7 purinergic receptor: a potential therapeutic target for lung cancer

  2020cites this paper
• The role of P2X4 receptors in chronic pain: A potential pharmacological target.

  2020cites this paper
• Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference

  2020cites this paper
• The role of CD28 in the prognosis of young lung adenocarcinoma patients

  2020cites this paper
• Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non–small-cell Lung Cancer

  2019cites this paper
• CÂNCER DE PULMÃO E SISTEMA PURINÉRGICO

  2019cites this paper
• P2X4R silence suppresses glioma cell growth through BDNF/TrkB/ATF4 signaling pathway

  2018cites this paper
• Extracellular ATP and P2 purinergic signalling in the tumour microenvironment

  2018cites this paper
• CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer

  2018cites this paper
• Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors

  2018cites this paper
• A review of metabolism-associated biomarkers in lung cancer diagnosis and treatment

  2018cites this paper
• Purinergic Receptors: Novel Targets for Cancer Immunotherapy

  2018cites this paper
• A Purinergic Trail for Metastases.

  2017cites this paper
• High expression of P2X7R is an independent postoperative indicator of poor prognosis in colorectal cancer.

  2017cites this paper
• Local Concentrations of CC-Chemokine-Ligand 18 Correlate with Tumor Size in Non-small Cell Lung Cancer and Are Elevated in Lymph Node-positive Disease.

  2016cites this paper
• The therapeutic potential of purinergic signalling.

  2010cites this paper